Deerfield Management Adds Cara Therapeutics Inc. (CARA) To Its Equity Portfolio

James E. Flynn’s Deerfield Management, in a filing with the Securities and Exchange Commission, reported a position in Cara Therapeutics Inc. (NASDAQ:CARA). The fund holds 350,000 shares of the Cara Therapeutics Inc. (NASDAQ:CARA), the stake amassing 1.55% of the common stock.

Cara Therapeutics

On Feb. 5, Cara Therapeutics Inc. (NASDAQ:CARA) announced the closing of its initial public offering of 5,750,000 shares of common stock at $11.00 per share. The offering included the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock at the same price to cover over-allotments.

Including the sale of the additional shares from the option, the net proceeds to the company from the initial public offering were about $55.9 million, after deducting underwriting discounts and commissions and estimated offering expenses, according to a news release.

Cara Therapeutics Inc. (NASDAQ:CARA) is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. The company possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics.

Recently, Deerfield reported adding KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) to its equity portfolio. The fund currently holds around 3.18 million shares of the company, the passive stake amassing 9.64% of the common stock.

On Feb. Deerfield revealed holding shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX). The fund reported ownership of around 1.29 million class E preferred shares. The securities can be converted into shares of common stock on the basis of 0.222 shares of common stock per one unit of preferred stock.

As of September 30, 2013, Deerfield owned around 5.0 million shares of NxStage Medical Inc. (NASDAQ:NXTM), with a reported value of about $66.15 million.

Disclosure: none

Recommended Reading:

Tiger Global Reduces Stake in TAL Education Group (ADR) (XRS) Again

Jeff Lignelli’s Incline Global Is Betting On These Stocks: Endo Health Solutions Inc (ENDP), Tesoro Corporation (TSO) & Others

Invesco Private Capital Boosts its Stake in Brookdale Senior Living, Inc. (BKD)

Dividend Stock Alert - Billionaire Robbins' Top Dividend Idea With 70% Upside Potential

Get Paid 3.5% Per Year While Waiting For The Stock Appreciate 70%

Larry Robbins' Glenview Capital Opportunity Fund returned 101.7% in 2013 and Robbins personally made $750 million. The same fund returned 25.3% in 2014. In this FREE REPORT we will share Robbins' top dividend idea that yields 3.5% and has been increasing its dividends for 39 consecutive years. Robbins thinks the stock has the potential to appreciate 70%.

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click Here to Read Comments
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!